Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PALMIRA: Palbociclib + 2nd Line Endocrine Therapy in HR+/HER2- ABC
NCT03809988Phase 2Completed
- Sponsor
- MEDSIR
- Start
- Apr 2019
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, randomised, open-label trial of palbociclib in breast cancer (2 arms), sponsored by MEDSIR. Primary endpoint: Progression-Free Survival up to 29 months. Started Apr 2019; status: completed.
02
Drugs
palbociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03809988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03809988.